Clark Estates Inc. NY Has $21.43 Million Position in Medtronic PLC $MDT

Clark Estates Inc. NY lowered its position in Medtronic PLC (NYSE:MDT) by 10.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 225,000 shares of the medical technology company’s stock after selling 25,000 shares during the quarter. Medtronic comprises 4.9% of Clark Estates Inc. NY’s investment portfolio, making the stock its 3rd largest holding. Clark Estates Inc. NY’s holdings in Medtronic were worth $21,429,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Riverbend Wealth Management LLC increased its stake in shares of Medtronic by 3.2% in the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock worth $332,000 after purchasing an additional 107 shares in the last quarter. Holistic Financial Partners boosted its holdings in Medtronic by 3.0% in the 3rd quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock worth $352,000 after buying an additional 109 shares during the period. Wynn Capital LLC grew its stake in Medtronic by 2.4% in the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after buying an additional 110 shares in the last quarter. Meridian Investment Counsel Inc. raised its holdings in Medtronic by 0.4% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock valued at $2,692,000 after acquiring an additional 110 shares during the period. Finally, Saxony Capital Management LLC lifted its position in shares of Medtronic by 3.8% during the third quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock worth $290,000 after acquiring an additional 112 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the company a “neutral” rating in a research report on Wednesday, November 19th. JPMorgan Chase & Co. cut their target price on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Mizuho upgraded Medtronic to a “strong-buy” rating in a research report on Wednesday, February 18th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Barclays reaffirmed an “overweight” rating and set a $118.00 price objective on shares of Medtronic in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.84.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory/coverage win in Japan for Medtronic’s Symplicity Spyral renal denervation device and management commentary that the company is investing in rollout and hiring to support market development — supports revenue upside from a growing hypertension therapy. Medtronic’s blood pressure device wins coverage nod in Japan
• Positive Sentiment: Analyst upgrade: Mizuho moved Medtronic to a “strong-buy,” which can support buying interest and short-term momentum. Mizuho upgrade reported via Zacks
• Neutral Sentiment: Industry growth tailwinds — a separate report highlights expansion in non‑invasive therapies (HIFU) and robotics/image‑guided systems; positive for device sector demand but not a direct Medtronic headline. HIFU Market Competitive Landscape Report 2025
• Neutral Sentiment: Competitive update — Intuitive Surgical (ISRG) reports faster international procedure growth, which underscores competitive dynamics in robotics and could pressure Medtronic’s robotics expectations over time. ISRG’s International Growth Outpaces US
• Neutral Sentiment: Company commentary and Q3 earnings materials are out (transcript available) showing mixed results: solid robotics wins but offset by some legal and expense items — provides context for guidance and valuation debate. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Multiple broker notes lowered expectations or targets (JPMorgan, Robert W. Baird; Leerink cut its target to $119) — analyst downgrades/target cuts weigh on sentiment and can amplify selling. JPMorgan low expectations
• Negative Sentiment: Planned layoffs: Medtronic will cut 81 roles at a California diabetes site as it readies the diabetes spin‑out; restructuring adds near‑term execution risk and uncertainty around the separations. Medtronic to cut 81 employees at California diabetes site
• Negative Sentiment: Broader skepticism in media pieces discussing mixed quarterly results, legal exposure and whether recent wins materially change Medtronic’s investment case — fuels analyst disagreement and investor caution. Mixed Q3 Results, Robotics Win and Legal Hit

Medtronic Stock Down 0.7%

MDT opened at $96.88 on Monday. The business’s fifty day simple moving average is $99.04 and its 200 day simple moving average is $96.75. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The stock has a market cap of $124.20 billion, a PE ratio of 26.99, a P/E/G ratio of 2.43 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).